Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A <sub>2</sub> Mass and Activity at Baseline and After Rosuvastatin Therapy

Audrey Y. Chu(University of Helsinki), Paul M. Ridker(Herlev Hospital), Bryan J. Barratt(AstraZeneca (United Kingdom)), Christie M. Ballantyne(Baylor College of Medicine), Daniel I. Chasman(Brigham and Women's Hospital), Harald Grallert(Helmholtz Zentrum München), Franco Guilianini(AstraZeneca (United Kingdom)), Josée Dupuis(Boston University), Fredrik Nyberg(National Academy of Medicine)
Circulation Cardiovascular Genetics
November 3, 2012
10.1161/circgenetics.112.963314
Cited by 41

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Biological, clinical and population relevance of 95 loci for blood lipids
|Nature|2010|3.7k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k